LENZ Therapeutics (LENZ) Operating Margin (2025 - 2026)

LENZ Therapeutics (LENZ) posted quarterly Operating Margin of 2321.67% for Q1 2026, down 854.51% quarter-over-quarter from 307.7% in Q4 2025.

LENZ Therapeutics (LENZ) Operating Margin (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has reported Operating Margin for 2 consecutive years, with 2321.67% the latest figure, recorded in Q1 2026.

In Q1 2026, Operating Margin changed N/A year-over-year to 2321.67%; the TTM figure through Mar 2026 stood at 1714.85% (changed N/A YoY), while the FY2025 annual figure was 1822.76%, changed N/A from the prior year.
Operating Margin slipped to 2321.67% in Q1 2026 per LENZ's latest filing, from 307.7% in the prior quarter.
Across five years, Operating Margin topped out at 307.7% in Q4 2025 and bottomed at 2321.67% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Vertex Pharmaceuticals	139.95 Bn	132.10 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn	30.15%
3	Argenx Se	65.71 Bn	60.52 Bn	1.37 Bn	32.54%
4	Moderna	60.45 Bn	55.31 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.24 Bn	37.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.64 Bn	10.25 Bn	668.28 Mn	-35.57%
8	Insmed	27.61 Bn	26.45 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.26 Bn	26.42 Bn	-	19.75%
10	LENZ Therapeutics	147.77 Mn	147.77 Mn	5.21 Mn	-622.89%

Download Data